Concepts (68)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 3 | 2024 | 545 | 1.500 |
Why?
|
| Immunization, Secondary | 1 | 2025 | 113 | 0.920 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2022 | 9 | 0.790 |
Why?
|
| Elephantiasis | 1 | 2022 | 2 | 0.790 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2022 | 7 | 0.780 |
Why?
|
| Arm | 1 | 2022 | 81 | 0.760 |
Why?
|
| Cancer Survivors | 1 | 2025 | 248 | 0.750 |
Why?
|
| Neurofibromatosis 1 | 1 | 2022 | 64 | 0.730 |
Why?
|
| Edema | 1 | 2022 | 140 | 0.720 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 97 | 0.610 |
Why?
|
| Gangliosides | 1 | 2019 | 73 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 128 | 0.580 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 473 | 0.550 |
Why?
|
| Immunity, Innate | 1 | 2019 | 418 | 0.520 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 824 | 0.460 |
Why?
|
| Immunotherapy | 1 | 2019 | 746 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1070 | 0.400 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1720 | 0.350 |
Why?
|
| Neoplasms | 1 | 2025 | 3030 | 0.330 |
Why?
|
| Tetanus Toxoid | 1 | 2025 | 50 | 0.240 |
Why?
|
| Hepatitis B Vaccines | 1 | 2025 | 45 | 0.240 |
Why?
|
| Spinal Cord Compression | 1 | 2024 | 33 | 0.230 |
Why?
|
| Infant | 3 | 2025 | 13181 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2024 | 75 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2024 | 72 | 0.220 |
Why?
|
| Pneumococcal Vaccines | 1 | 2025 | 172 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 93 | 0.190 |
Why?
|
| Female | 6 | 2025 | 71818 | 0.190 |
Why?
|
| Bloom Syndrome | 1 | 2021 | 5 | 0.180 |
Why?
|
| Dyspnea | 1 | 2022 | 160 | 0.180 |
Why?
|
| Benzimidazoles | 1 | 2022 | 136 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 793 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 236 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2025 | 14818 | 0.170 |
Why?
|
| Child | 4 | 2025 | 25816 | 0.170 |
Why?
|
| Mexican Americans | 1 | 2021 | 207 | 0.160 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 65 | 0.150 |
Why?
|
| Immunologic Memory | 1 | 2019 | 199 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 211 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1106 | 0.140 |
Why?
|
| Humans | 8 | 2025 | 134032 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 835 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1976 | 0.130 |
Why?
|
| Adolescent | 2 | 2025 | 20581 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 407 | 0.130 |
Why?
|
| Proteomics | 1 | 2020 | 598 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1764 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 696 | 0.120 |
Why?
|
| Male | 4 | 2025 | 66022 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2024 | 6601 | 0.100 |
Why?
|
| Cytokines | 1 | 2019 | 1400 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 810 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3781 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4801 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6304 | 0.070 |
Why?
|
| Mice | 1 | 2019 | 19030 | 0.050 |
Why?
|
| RecQ Helicases | 1 | 2021 | 64 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 190 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 561 | 0.040 |
Why?
|
| Leucine | 1 | 2020 | 312 | 0.040 |
Why?
|
| Animals | 1 | 2019 | 36524 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 293 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 1698 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 549 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1710 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2936 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3486 | 0.020 |
Why?
|